ShareProphets

The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join ShareProphets at less than 2p per article

> All the big AIM fraud exposés

> 300 articles and podcasts a month

> Hot share tips

> Original investigations by our experienced team

> No ads, no click-bait, no auto-play videos

Find out more

Malcolm Stacey's share tip of the year No 1 - buy Advanced Oncotherapy

By Malcolm Stacey | Friday 25 December 2015


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I can’t exactly remember which New Year shares I tipped last year. But I recall that one of them Zytronic (ZYT) which does wonders with touch technology, was a cracking performer - I got a gold star for it in the performance table!
 
Though another share I’ve drawn your attention to quite a lot has had a more up and down career. I bought Advanced Oncotherapy (AVO) at around 2p and it’s about 7p now.
 
But so far, I’m losing quite a bit of dosh on it. That’s all because of that fateful trip I made last April to attend the wonderful UK Investor Show in Westminster.
 
As the train ride progressed, I bought a load more AVO shares. then noticed that the share, which had snowballed all week, was now approaching 17p. I was about to sell at this point, because such a huge jump is rarely sustained. Then I lost radio signal.
 
By the time I regained it, the stock had begun a slow journey down. Reasoning, daftly, that it would get a second wind, I hung onto the share. So now I am adrift by quite a bit.
 
And yet there has not been any spoilers to squash Advanced's progress. It’s just that little good news has come through, either.
 
That doesn’t worry me, because with a new technology which is, really, really useful - like zapping cancer tumours - the orders are bound to flood in eventually.
 
But will the technology, which is based on discoveries at the Hadron Collider project, come to full fruition? Well, a lot of people think so. and I’m told the efficacy of the treatment is already more or less proven.
 
So if better news comes in 2016 expect that fickle share price to hit 17p again. That would make it a two and half bagger by my reckoning.
 
We’re good at maths in the Punter’s Return.


Filed under:


Never miss a story.




This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.


More on AVO


Comments

4 comments

  1. Good pick – my Number 1 too – expect a similar rise to 17p in 2016, but really expecting it to motor in 2017 when the sky could really be the limit. Either way – it’s at a great entry price today!

  2. Thanks Gaters. I sometimes loose a bit of confidence in AVO whose share path has been generally down lately. But then my common sense kicks in. Hope you’re having a cool yule.


  3. Mould Capital

    I also have a small position in AVO, it is just one of those cases where you need to buy and hold and be patient.

  4. Up 15% today. You lucky people!


Enter your comment below. Fields marked * are required. You must preview your comment first before finally posting.


Site by Everywhen